Publications

  1. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20; 42 (30):3581-3592 Epub 2024 Aug 02
    View PubMed
  2. Atallah-Yunes SA, Rees MJ, Witzig TE, Habermann TM, Munoz J, Iqbal M, McPhail ED, Nowakowski GS. CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under. Haematologica. 2024 Oct 10 [Epub ahead of print]
    View PubMed
  3. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Alhaj Moustafa M, Murthy HS, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy. Blood Adv. 2024 Sep 24; 8 (18):4877-4885
    View PubMed
  4. Zinzani PL, Munoz J, Trotman J. Current and future therapies for follicular lymphoma. Exp Hematol Oncol. 2024 Aug 22; 13 (1):87
    View PubMed
  5. Deshpande A, Munoz J, Kurzrock R. Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma. J Immunother Precis Oncol. 2024 Aug; 7 (3):201-204 Epub 2024 Aug 19
    View PubMed
  6. Saifi O, Breen WG, Rule WG, Lin Y, Munoz J, Kharfan-Dabaja MA, Peterson JL. Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma. JAMA Oncol. 2024 Jul 1; 10 (7):979-981
    View PubMed
  7. Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 Jun 27; 143 (26):2722-2734
    View PubMed
  8. Deshpande A, Munoz J, Dabak V, Hanbali A, Kurzrock R. Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1. J Immunother Precis Oncol. 2024 May; 7 (2):122-125 Epub 2024 May 02
    View PubMed
  9. Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Muller F, Bethge W, Munoz J, Mohty R, Bucklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024 Apr 23; 8 (8):1857-1868
    View PubMed
  10. Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer Treat Rev. 2024 Mar; 124:102691 Epub 2024 Jan 17
    View PubMed
  11. Oluwole OO, Forcade E, Munoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ, van Meerten T. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024 Mar; 59 (3):366-372 Epub 2024 Jan 04
    View PubMed
  12. Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8 (4):1042-1050
    View PubMed
  13. Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jan; 30 (1):77.e1-77.e15 Epub 2023 Oct 27
    View PubMed
  14. Saifi O, Lester SC, Breen WG, Rule WG, Lin Y, Bennani NN, Rosenthal A, Munoz J, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach. Am J Hematol. 2024 Jan; 99 (1):124-134 Epub 2023 Nov 11
    View PubMed
  15. Gaulin C, Craig F, Fortin Ensign S, Robetorye R, Gibson S, Kelemen K, Khera N, Leis J, Tsang M, Rosenthal A, Munoz J, Palmer J, Hilal T. Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms. Leuk Lymphoma 2023 Dec; 64 (14):2347-2350 Epub 2023 Sept 07
    View PubMed
  16. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023 Nov 01; 108(11):2982-2992.
    View PubMed
  17. Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bucklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov; 98 (11):1699-1710 Epub 2023 Aug 16
    View PubMed
  18. Huff D, Fortin Ensign S, Ryan MS, Palmer J, Munoz J. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review. J Immunother Precis Oncol. 2023 Nov; 6 (4):198-202 Epub 2023 Dec 02
    View PubMed
  19. Tam CS, Munoz JL, Seymour JF, Opat S. Correction: Zanubrutinib: past, present, and future. Blood Cancer J. 2023 Oct 2; 13 (1):154 Epub 2023 Oct 02
    View PubMed
  20. Richards AB, Fletcher GP, Munoz JL. Facial Nerve Palsy After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clin Proc. 2023 Oct; 98 (10):1579-1580
    View PubMed
  21. Tam CS, Munoz JL, Seymour JF, Opat S. Zanubrutinib: past, present, and future. Blood Cancer J. 2023 Sep 11; 13 (1):141 Epub 2023 Sept 11
    View PubMed
  22. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Khurana A, Villasboas JC, Johnston PB, Ansell SM, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2023 Aug 1; 116 (5):999-1007 Epub 2022 Dec 21
    View PubMed
  23. Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Jul; 29 (7):440-448 Epub 2023 Apr 07
    View PubMed
  24. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  25. Munoz J, Hoffmann M, Westin J, Vassilakopoulos TP, Garcia-Sancho AM, Rueda-Dominguez A, Jurczak W, Kwiatek M, Bouzani M, Gkasiamis A, Patel A, Boucaud F, Li J, Nowakowski GS. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:584-586
    View PubMed
  26. Locke FL, Lekakis L, Eradat H, Munoz J, Tees M, de Vos S, Nath R, Stevens D, Malik S, Popplewell L, Hamadani M, Oluwole O, Perales M, Miklos D, Fisher P, Goyal L, Navale L, Kaufman G, Kai K, Balakumaran A, Neelapu S. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:85-86
    View PubMed
  27. Ip A, Rosenthal A, Mutebi A, Wang T, Jun M, Wang A, Yu J, Brodkin S, Sacchi M, Kalsekar A, Munoz J. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:433-434
    View PubMed
  28. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May 11; 141 (19):2307-2315
    View PubMed
  29. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 May 10; 41 (14):2594-2606 Epub 2023 Feb 08
    View PubMed
  30. Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023 Apr 25; 7 (8):1572-1576
    View PubMed
  31. Munoz J, Sarosiek S, Castillo JJ. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. Oncologist. 2023 Apr 6; 28 (4):309-318
    View PubMed
  32. Munoz J, Wang M. Glabellar mass in a case of mantle-cell lymphoma treated by CAR T-cell therapy. Lancet. 2023 Mar 25; 401 (10381):1037-1038
    View PubMed
  33. Rosenthal AC, Munoz JL, Villasboas JC. Clinical advances in epigenetic therapies for lymphoma. Clin Epigenetics. 2023 Mar 4; 15 (1):39 Epub 2023 Mar 04
    View PubMed
  34. Deshpande A, Munoz J, Kelemen K, Dabak V, Hanbali A, Kurzrock R. Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver. J Immunother Precis Oncol. 2023 Feb; 6 (1):56-58 Epub 2022 Dec 27
    View PubMed
  35. Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping JRY, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A. The ir2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory dlbcl: a multicentre, non-randomised, open-label phase 2 study. eClinicalMedicine. 2023 Feb; 56:101779
  36. Casulo C, Santoro A, Cartron G, Ando K, Munoz J, Le Gouill S, Izutsu K, Rule S, Lugtenburg P, Ruan J, Arcaini L, Casadebaig ML, Fox B, Kilavuz N, Rettby N, Dell'Aringa J, Taningco L, Delarue R, Czuczman M, Witzig T. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial. Cancer Rep (Hoboken). 2023 Jan; 6 (1):e1662 Epub 2022 July 19
    View PubMed
  37. Ip A, Rosenthal A, Mutebi A, Wang T, Jun M, Wang A, Yu J, Brodkin S, Sacchi M, Kalsekar A, Munoz J. Comparison of clinical outcomes in patients with relapsed/refractory large b-cell lymphoma treated with epcoritamab versus chemoimmunotherapy. Hematological Oncology. 2023; 41 (S2):433-4
  38. Granroth G, Rosenthal A, McCallen M, Coughlin C, Benson H, Palmer J, Castro JE, Munoz J. Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective. Curr Oncol Rep. 2022 Dec; 24 (12):1863-1872 Epub 2022 Nov 07
    View PubMed
  39. Fortin Ensign SP, Gaulin C, Hrachova M, Ruff M, Harahsheh E, Vicenti K, Castro J, Munoz J, Rosenthal A, Mrugala MM. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Curr Treat Options Oncol. 2022 Dec; 23 (12):1845-1860 Epub 2022 Dec 16
    View PubMed
  40. Munoz J, Paludo J, Sarosiek S, Castillo JJ. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenstrom Macroglobulinemia. Cells. 2022 Oct 19; 11 (20)
    View PubMed
  41. Munoz JL, Wang Y, Jain P, Wang M. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. Curr Oncol Rep. 2022 Oct; 24 (10):1299-1311 Epub 2022 May 21
    View PubMed
  42. Iqbal M, Bansal R, Yassine F, Gandhi S, Rosenthal A, Moustafa MA, Li Z, Craver EC, Mohty R, Murthy H, Ayala E, Tun H, Munoz J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Oct; 28 (10):668.e1-668.e6 Epub 2022 July 14
    View PubMed
  43. Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 (10):753-759 Epub 2022 May 23
    View PubMed
  44. Munoz J, Larsen J. Calvarium indentations in multiple myeloma and CAR T-cell therapy. Lancet. 2022 Jul 30; 400 (10349):391
    View PubMed
  45. Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar S, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022 Jun 14; 6 (11):3268-3279
    View PubMed
  46. Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022 Jun; 58 (6):283-298
    View PubMed
  47. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 Apr; 28 (4):735-742 Epub 2022 Mar 21
    View PubMed
  48. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 Mar; 196 (5):1209-1218 Epub 2021 Dec 16
    View PubMed
  49. Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, Jager U, Manges RF, Trumper L, Everaus H, Kalakonda N, Brown P, Jorgensen JM, Cunningham D, Dell'Aringa J, Fox B, Rubio ND, Kilavuz N, Casadebaig ML, Manzke O, Munoz J. Safety and efficacy of durvalumab with R-CHOP or R(2)-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. Int J Hematol. 2022 Feb; 115 (2):222-232 Epub 2021 Nov 19
    View PubMed
  50. Gathers DA, Galloway E, Kelemen K, Rosenthal A, Gibson SE, Munoz J. Primary Effusion Lymphoma: A Clinicopathologic Perspective. Cancers (Basel). 2022 Jan 30; 14 (3)
    View PubMed
  51. Albanyan O, Chavez J, Munoz J. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Ther Adv Hematol. 2022; 13:20406207221141511 Epub 2022 Dec 06
    View PubMed
  52. Deshpande A, Munoz J. Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. Front Oncol. 2022; 12:948513 Epub 2022 Sept 12
    View PubMed
  53. Munoz J, Wang Y, Jain P, Wang M. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Ther Adv Hematol. 2022; 13:20406207221093980 Epub 2022 May 27
    View PubMed
  54. Deshpande A, Munoz J. Zanubrutinib in Treating Waldenstrom Macroglobulinemia, the Last Shall Be the First. Ther Clin Risk Manag. 2022; 18:657-668 Epub 2022 June 23
    View PubMed
  55. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Jan; 23 (1):91-103 Epub 2021 Dec 08
    View PubMed
  56. Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022 Jan; 166:171-179. Epub 2021 Dec 07.
    View PubMed
  57. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2021 Dec 11 [Epub ahead of print]
    View PubMed
  58. Saifi O, Breen W, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Murthy HS, Lin Y, Kharfan-Dabaja M, Hoppe BS, Peterson JL. Radiation Therapy as Bridging Treatment to CAR T Cell Therapy in Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S132
    View PubMed
  59. Tam CS, Dimopoulos MA, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen RG, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb DJ, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2021 Nov 1 Epub 2021 Nov 01
    View PubMed
  60. Oluwole OO, Bouabdallah K, Munoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021 Aug; 194 (4):690-700 Epub 2021 July 22
    View PubMed
  61. Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021 Jun 22; 5 (12):2577-2585
    View PubMed
  62. Straus DJ, Dlugosz-Danecka M, Connors JM, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021 Jun; 8 (6):e410-e421
    View PubMed
  63. Munoz J, Follows GA, Nastoupil LJ. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Target Oncol. 2021 May; 16 (3):295-308 Epub 2021 Mar 09
    View PubMed
  64. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 2021 Apr 1; 137 (13):1832-1835
    View PubMed
  65. Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Rossi JM, Bot A, Zheng LQ, Vezan R, Bashir Z, Kim JJ, Chu R, Neelapu SS. Long-term survival and gradual recovery of b cells in patients with refractory large b-cell lymphoma treated with axicabtagene ciloleucel Clinical Advances in Hematology & Oncology. 2021 Mar; 19 (3):4-5
  66. Coleman M, Belada D, Casasnovas RO, Gressin R, Lee HP, Mehta A, Munoz J, Verhoef G, Corrado C, DeMarini DJ, Zhao W, Li J, Fay K. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma. 2020 Nov 3; 1-9 Epub 2020 Nov 03
    View PubMed
  67. Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, Munoz J, Tedeschi A, Roberts AW, Seymour JF, Atwal SK, Yu Y, Novotny W, Holmgren E, Tan Z, Hilger JD, Huang J, Tam CS. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood. 2020 Oct 29; 136 (18):2027-2037
    View PubMed
  68. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep 20; 38 (27):3119-3128 Epub 2020 May 13
    View PubMed
  69. Hilal T, Munoz J. Choosing Wisely(R) in Hematology: Have We Made a Difference? Curr Hematol Malig Rep. 2020 Aug; 15 (4):241-247
    View PubMed
  70. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 Jun 4; 135 (23):2106-2109
    View PubMed
  71. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 Apr 2; 382 (14):1331-1342
    View PubMed
  72. Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020 Mar 5; 135 (10):735-742
    View PubMed
  73. Dreyling M, Santoro A, Mollica L, Leppa S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Ozcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2019 Dec 23 [Epub ahead of print]
    View PubMed
  74. Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019 Sep 26; 134 (13):1024-1036 Epub 2019 July 22
    View PubMed
  75. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12; 134 (11):851-859 Epub 2019 July 24
    View PubMed
  76. Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019 Jul; 20 (7):998-1010 Epub 2019 May 14
    View PubMed
  77. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan; 20 (1):31-42 Epub 2018 Dec 02
    View PubMed
  78. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2 Epub 2018 Sept 13
    View PubMed
  79. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28; 377 (26):2531-2544 Epub 2017 Dec 10
    View PubMed
  80. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 Jul; 78 (1):167-71 Epub 2016 June 10
    View PubMed
  81. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 Apr; 15 (4):533-47 Epub 2016 Mar 23
    View PubMed
  82. Munoz J, Wheler J, Kurzrock R. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Rev. 2015 Dec; 34 (4):547-61
    View PubMed
  83. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb; 19 (103):101-8
    View PubMed
  84. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb; 19 (103):109-16
    View PubMed
  85. Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015 Jan 20; 6 (2):592-603
    View PubMed
  86. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014 Dec; 3 (12):1435-43 Epub 2014 Nov 05
    View PubMed
  87. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec; 18 (101):323-30
    View PubMed
  88. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18 (101):331-9
    View PubMed
  89. Munoz J, Janku F, Cohen PR, Kurzrock R. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014 Jul; 89 (7):985-96 Epub 2014 May 09
    View PubMed
  90. Munoz J, Dhillon N, Janku F, Watowich SS, Hong DS. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014 May; 19 (5):536-44 Epub 2014 Apr 04
    View PubMed
  91. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014; 1 (10):614-623 Epub 2014 Oct 22
    View PubMed
  92. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10; 31 (20):e351-2 Epub 2013 June 03
    View PubMed
  93. Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013 Jul 10; 31 (20):e360-3 Epub 2013 June 03
    View PubMed
  94. Munoz J, Kurzrock R. Unilateral proptosis. JAMA. 2013 Feb 13; 309 (6):605-6
    View PubMed
  95. Munoz J, Vekaria M, Hanbali A, Janakiraman N. Progression of double-hit lymphoma in the midst of R-hyper CVAD. Am J Hematol. 2013 Jan; 88 (1):87-8 Epub 2012 Apr 10
    View PubMed
  96. Munoz J, Hughes A, Guo Y. Mucormycosis-associated intracranial hemorrhage. Blood Coagul Fibrinolysis. 2013 Jan; 24 (1):100-1
    View PubMed
  97. Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013; 127-34
    View PubMed
  98. Munoz J, Kuriakose P. Antibiotic-refractory sinusitis. JAMA. 2012 Dec 12; 308 (22):2399-400
    View PubMed
  99. Munoz J, Schering J, Lambing A, Neal S, Goyert G, Green PM, Hanbali A, Raman S, Kuriakose P. The dilemma of inherited dysfibrinogenemia during pregnancy. Blood Coagul Fibrinolysis. 2012 Dec; 23 (8):775-7
    View PubMed
  100. Munoz J, Kurzrock R. Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol. 2012 Nov; 9 (11):631-42 Epub 2012 Sept 11
    View PubMed
  101. Munoz J, Guo Y. Familial history of bone tumors. JAMA. 2012 Oct 10; 308 (14):1476-7
    View PubMed
  102. Munoz J, Hanbali A. Reactive eosinophilia and thrombosis. Blood. 2012 Oct 4; 120 (14):2785
    View PubMed
  103. Munoz J, Janakiraman N. Relapse of liver amyloidosis 6 years after autologous stem cell transplantation. Am J Hematol. 2012 Sep; 87 (9):926 Epub 2012 May 28
    View PubMed
  104. Munoz J, Kuriakose P. Lymphocytosis: T-cell large granular lymphocyte leukemia. Blood. 2012 Aug 23; 120 (8):1543
    View PubMed
  105. Munoz J, Namo S, Stoltenberg M, Chapman R. Salmonella-related mycotic aortic aneurysm heralding a diagnosis of multiple myeloma. Am J Hematol. 2012 Aug; 87 (8):820-1 Epub 2012 Mar 31
    View PubMed
  106. Munoz J, Barthel B. Leukemic phase of Burkitt lymphoma. Blood. 2012 Jul 12; 120 (2):247
    View PubMed
  107. Munoz J, Ali H. A pain in the neck. JAMA. 2012 Jul 11; 308 (2):182-3
    View PubMed
  108. Gamalski S, Munoz J, Diaz-Kuan A, Wollner I. Germ cell tumour of the trachea. BMJ Case Rep. 2012 Jul 5; 2012 Epub 2012 July 05
    View PubMed
  109. Munoz J, Rana J, Inamdar K, Nathanson D, Janakiraman N. Blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2012 Jul; 87 (7):710 Epub 2011 Sept 26
    View PubMed
  110. Munoz J, Michel Ortega R, Celzo F, Donthireddy V. 'Tumour-induced osteomalacia'. BMJ Case Rep. 2012 Jun 25; 2012 Epub 2012 June 25
    View PubMed
  111. Munoz J, Donthireddy V. CNS hyperleukocytosis. Blood. 2012 Jun 21; 119 (25):5953
    View PubMed
  112. Munoz J, Hughes A. Thrombotic thrombocytopenic purpura after autologous peripheral stem cell transplantation. Blood. 2012 Jun 14; 119 (24):5620
    View PubMed
  113. Munoz J, Naing A, Qi M, Kurzrock R. Cutaneous Castleman disease. Br J Haematol. 2012 Jun; 157 (6):652 Epub 2012 Apr 26
    View PubMed
  114. Munoz J, Sanchez BE, Wang D. Histiocytic sarcoma of the thyroid. Am J Hematol. 2012 May; 87 (5):531 Epub 2011 Nov 25
    View PubMed
  115. Ali S, Pimentel JD, Munoz J, Shah V, McKinnon R, Divine G, Janakiraman N. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch Pathol Lab Med. 2012 May; 136 (5):532-8
    View PubMed
  116. Munoz J, Hanbali A. A young patient with multiple myeloma. Blood. 2012 Mar 29; 119 (13):2979
    View PubMed
  117. Munoz J, Hanbali A. Blue sclerae. JAMA. 2012 Mar 28; 307 (12):1310-1
    View PubMed
  118. Munoz J, Kuriakose P. Rash in an immunocompromised patient. JAMA. 2012 Feb 8; 307 (6):612-3
    View PubMed
  119. Munoz J, Guo Y. Leukocytosis: the mysteries within. Am J Hematol. 2012 Feb; 87 (2):197 Epub 2011 Aug 03
    View PubMed
  120. Munoz J, Shareef N, Donthireddy V. Cytomegalovirus-induced haemophagocytic lymphohistiocytosis syndrome. BMJ Case Rep. 2012 Jan 23; 2012
    View PubMed
  121. Munoz J, Sheqwara J, Hanbali A, Wollner I. Fulminant Malignant Hepatic Failure. J Liver. 2012; 1:105.
  122. Munoz J, Kuriakose P. Fatigue improvement after eculizumab in paroxysmal nocturnal hemoglobinuria: apropos of a case. J Palliative Care Med. 2012; 2:5.
  123. Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95 (1):1-2 Epub 2011 Dec 15
    View PubMed
  124. Munoz J, Romero W, Hanbali A, Kuriakose P. Paraneoplastic syndromes associated to Hodgkin's lymphoma. BMJ Case Rep. 2011 Dec 13; 2011
    View PubMed
  125. Munoz J, Ferrari N, Kuriakose P. Iron-overload myopathy. Int J Hematol. 2011 Dec; 94 (6):503-4 Epub 2011 Nov 03
    View PubMed
  126. Munoz J, Guo Y. Basophilic stippling: a lead to the diagnosis. Blood. 2011 Nov 17; 118 (20):5370
    View PubMed
  127. Munoz J, Hanbali AS. Epidermal growth factor receptor-induced hirsutism and trichomegaly. Mayo Clin Proc. 2011 Nov; 86 (11):e50
    View PubMed
  128. Munoz J, Chacra W, Hanbali A, Ali H. Sister Mary Joseph's nodule. BMJ Case Rep. 2011 Aug 17; 2011
    View PubMed
  129. Munoz J, Stoltenberg M, Mohd Khushman//Amr Hanbali. Severe lactic acidosis in a patient with metastatic prostate cancer. J Cancer Res Ther. 2011 Apr-Jun; 7 (2):201-2
    View PubMed